Pulmonary Associates, Phoenix, AZ Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2007
NCT00515164
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Pulmonary Associates

Active Ingredients

Drugs in Phase 2 Trials (1)

aluminum hydroxide (Gaviscon) (1 trial)

Drugs in Phase 1 Trials (1)

tebipenem (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Emphysema (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2